Nasdaq:CNTX
Context Therapeutics Inc.
A clinical-stage biotech firm developing transformative therapies for severe autoimmune conditions and oncology.
Key Metrics
Investment Thesis
Bull Case
An investor might buy CNTX for its potential as a turnaround story if a key clinical trial succeeds, offering massive upside from current minimal valuation. The company's strong liquidity position relative to its annual burn rate provides a runway that could support multiple years of development before requiring further dilution. Success in the severe autoimmune space would validate their platform technology and establish a high-value commercial franchise.
Bear Case
An investor should avoid CNTX due to the complete absence of revenue and a consistent, deepening trend of net losses over the last three years. The company is heavily dependent on external capital markets for survival, creating vulnerability if interest rates remain high or equity markets cool. With $26.7M in annual operating losses and no commercial sales, the probability of total value erosion before clinical success remains extremely high.
About Context Therapeutics Inc.
Context Therapeutics (CNTX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for severe autoimmune diseases and cancer. Operating primarily in the United States and seeking global expansion, the company leverages its proprietary technology platform to advance candidates through preclinical and clinical stages.
Analysis
Management Discussion
Management has aggressively pursued capital raising through equity issuance, evidenced by $109.3M in cash flow from financing activities, yet this has not halted the widening operational deficit. While non-cash adjustments like depreciation are negligible due to the early-stage nature of the assets, the company continues to burn approximately $27M annually in net profit while holding roughly $94M in cash.
Industry Overview
The biopharmaceutical industry is characterized by long development cycles, high failure rates, and significant capital requirements to bring new therapies to market. Companies like CNTX operate in a pre-commercial phase where value is derived entirely from intellectual property and pipeline potential rather than current financial performance. Regulatory hurdles for novel mechanisms of action can be steep but successful approvals can lead to blockbuster-level returns.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $15.4M | $25.1M | $29.9M |
| Operating Income | $-15.4M | $-25.1M | $-29.9M |
| G&A | $7.8M | $7.3M | $7.2M |
| Stock-Based Comp | $976.4K | $1.1M | $841.9K |
| D&A | $9.3K | $12.0K | $10.9K |
| Other OpEx | $7.6M | $17.8M | $22.7M |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Income | — | — | $3.2M |
| Pre-Tax Income | $-15.4M | $-25.1M | $-29.9M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-15.4M | $-25.1M | $-29.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-14.8M | $-24.0M | $-26.7M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-14.8M | $-24.0M | $-26.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $37.9M | $16.0M | $97.9M |
| Cash & Equivalents | $35.5M | $14.4M | $94.4M |
| Prepaid Expenses | $2.4M | $1.6M | $3.5M |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $112.3K | $15.5K | $230.8K |
| PP&E (Net) | $27.6K | $15.5K | $12.0K |
| Operating Leases | $52.0K | $0 | $218.8K |
| Other LT Assets | $32.8K | $0 | $0 |
| Total Assets | $38.0M | $16.1M | $98.1M |
| Current Liabilities | $3.2M | $4.2M | $2.7M |
| Accounts Payable | $936.3K | $2.4M | $1.5M |
| Current Leases | $55.1K | $0 | $107.3K |
| Other Current Liab | $0 | $0 | $0 |
| Long-Term Liabilities | $0 | $0 | $112.1K |
| LT Operating Leases | — | — | $112.1K |
| Other LT Liab | — | — | $0 |
| Total Liabilities | $3.2M | $4.2M | $2.9M |
| Shareholders' Equity | $34.8M | $11.9M | $95.3M |
| Paid-In Capital | $78.8M | $79.9M | $190.0M |
| Retained Earnings | $-44.1M | $-68.1M | $-94.8M |
| Total L&E | $38.0M | $16.1M | $98.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-14.8M | $-24.0M | $-26.7M |
| Non-Cash Adjustments | $26.6K | $2.7M | $11.9M |
| Working Capital Changes | $1.3M | $192.6K | $261.7K |
| Cash from Operations | $-13.5M | $-21.0M | $-14.6M |
| Capital Expenditures | $36.8K | $0 | $7.3K |
| Cash from Investing | $-536.8K | $0 | $-14.8M |
| Cash from Financing | $-102.1K | $0 | $109.3M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-14.2M | $-21.0M | $80.0M |
| Beginning Cash | $49.7M | $35.5M | $14.4M |
| Ending Cash | $35.5M | $14.4M | $94.4M |
Frequently Asked Questions
How does Context Therapeutics Inc. make money?
The company's financials indicate a purely research and development model with no commercial revenue streams. Operations are segmented by therapeutic area (autoimmune and oncology), relying entirely on cash reserves, equity financing, and grant funding to support high-cost clinical trial activities rather than sales of finished goods or services.
What are the main risks for CNTX?
The company faces significant risk from cash burn, as operating losses have widened from $14.8M in 2022 to $26.7M in 2024 without any revenue generation. There is substantial dilution risk for existing shareholders due to repeated equity issuances totaling over $190M in paid-in capital to fund operations. Clinical trial failures or regulatory rejections of their pipeline candidates would result in a total loss of invested R&D capital. The absence of commercial revenue makes the company highly sensitive to macroeconomic conditions affecting venture capital and public market financing.
What is CNTX's competitive advantage?
CNTX possesses a proprietary discovery platform capable of identifying novel targets for severe autoimmune diseases with few current approved treatments. The company maintains a strong balance sheet relative to its operational scale, evidenced by substantial cash and equivalents against minimal liabilities. Its focus on unmet medical needs in rare disease sub-sectors offers high potential reward upon regulatory approval.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.